Definium Therapeutics, Inc. (DFTX), formerly Mind Medicine (MindMed), is a clinical-stage biopharmaceutical company developing drug candidates for brain health disorders. Its lead programs are DT120, in Phase 3 for generalized anxiety disorder (GAD) and major depressive disorder (MDD), and DT402, in Phase 2a for autism spectrum disorder.
Because the company is pre-revenue, its DFTX stock forecast rests almost entirely on analyst price targets tied to clinical and regulatory milestones rather than earnings multiples. Reviewing roughly 15 distinct, current analyst targets from firms including H.C. Wainwright ($70), RBC Capital ($66), J.P. Morgan ($84), Bank of America Securities ($91), LifeSci Capital ($78), Stifel ($67), JonesTrading ($90), Canaccord Genuity ($78), Baird ($79), Oppenheimer ($75), Needham ($66), Wells Fargo ($72), and Piper Sandler ($75) produces a mean of about $74, which rounds to a central target of $75. The range is unusually wide — $55 to $91 — reflecting genuine disagreement about DT120's probability of success.
Independent aggregators report similar but not identical figures, a reminder that the "analyst consensus" is not a single official number. S&P Global's poll of 19 analysts shows an average near $72.56, while MarketBeat's larger sample averages closer to $66. The rating distribution is effectively unanimous on the bullish side, with no Holds or Sells among current ratings. Analyst reasoning centers on the strength of DT120's clinical data, particularly a reported 8.1-point MADRS (Montgomery-Åsberg Depression Rating Scale) improvement over placebo at week six, and on the company's funding runway.
With the stock trading near $35 and a 52-week range of $10.47 to $49.70, the path from $35 to $75 requires roughly a 114% advance — a very large move by any standard. Definium's market capitalization is approximately $4.5 billion to $4.9 billion, despite generating no product revenue and reporting a trailing net loss around $354 million.
Because there are no earnings to anchor valuation, any sustained move toward $75 would most plausibly be event-driven: positive top-line results from the Phase 3 GAD program or the ASCEND MDD trial, followed by a credible regulatory filing timeline. The company's cash position of roughly $1.08 billion reduces near-term dilution risk, but the stock's high beta near 2.2 means price swings are often sharp and sentiment-driven rather than fundamental.
On a technical basis, DFTX trades near $35, below its 50-day moving average of roughly $37.77 but well above its 200-day moving average near $29.60, suggesting a still-positive long-term trend with near-term consolidation. The prior 52-week high near $49.70 acts as the first major resistance level, with the psychological $50 mark just above it. On the downside, the $30 area — reinforced by the 200-day average — is the most significant support zone. A decisive break above the $49–$50 band would be a notable technical milestone on the way toward the $75 target.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms do not always state an explicit timeframe, and horizons can differ. Investors should watch the Phase 3 GAD and ASCEND MDD data readouts, any regulatory filing updates, quarterly cash-burn and cash-position disclosures, and revisions to analyst targets. Rating changes, particularly any first Hold or downgrade from the current unanimous Buy base, would be an important sentiment signal.
For traders monitoring a high-volatility name like Definium, AI Daily Buy/Sell Signals from Tickeron offer an additional layer of structure. The system uses artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Rather than relying on a single opinion, traders can use these signals to discover opportunities, monitor existing positions, and spot shifting trends more efficiently — especially useful for a biotech stock whose price can move rapidly on news. Explore the AI Daily Buy/Sell Signals to see how automated monitoring can support your process.
The question of whether DFTX can reach $75 depends almost entirely on clinical execution rather than earnings. The $75 central target — the rounded mean of roughly 15 current analyst targets spanning $55 to $91 — implies a roughly 114% advance from a price near $35, a very large move. The case for it rests on DT120's encouraging data, a strong cash position, and unanimous bullish coverage. The case against it rests on binary clinical risk, the absence of revenue, and a wide dispersion in analyst views. The next Phase 3 readouts and any shift in the analyst rating mix will be the clearest indicators of whether that gap can close. No outcome is guaranteed, and the target is a research estimate, not a promise.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, DFTX has been loosely correlated with RLAY. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if DFTX jumps, then RLAY could also see price increases.
| Ticker / NAME | Correlation To DFTX | 1D Price Change % | ||
|---|---|---|---|---|
| DFTX | 100% | -3.87% | ||
| RLAY - DFTX | 45% Loosely correlated | +1.32% | ||
| IDYA - DFTX | 41% Loosely correlated | -2.33% | ||
| PGEN - DFTX | 40% Loosely correlated | +1.20% | ||
| PRAX - DFTX | 40% Loosely correlated | -3.37% | ||
| CGEM - DFTX | 40% Loosely correlated | -1.98% | ||
More | ||||